Investors / United States / SR One
SR One
Venture capital · Redwood City, CA, United States · North America
SR One is a biotechnology venture capital firm that partners with founders and entrepreneurs to translate science into medicines. It takes a build-and-back approach to its investments, focusing on companies with strong fundamentals, a defined development pathway, and novel approaches to disease.
Invests inHealthcare & Biotech
In its own wordsbiotechnologylife scienceshealthcaretherapeutics
Your fit with SR One
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsSR One lists 42 checked portfolio companies on its own site and is named in 16 funding rounds, 6 of them as lead. Its most frequent entry is Series A, 43% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 65% of its companies are based in United States. It invests most often alongside RA Capital, Pivotal Life Sciences and NEA.
Counts come from funding rounds that name SR One, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not SR One's whole history. Rounds on record name 14 companies; its own site lists 42. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundSR One does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 43% |
| Series B | 29% |
| Growth | 29% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 1 | 1 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 8 | 3 |
| '26 | 7 | 2 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 78th | 42 companies |
| Recent activity | 93th | 8 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 98th | 33% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 8 |
| Pivotal Life Sciences | 6 |
| NEA | 4 |
| Atlas Venture | 3 |
| Catalio Capital Management | 3 |
| F-Prime Capital | 3 |
| Foresite Capital | 3 |
| Frazier Life Sciences | 3 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers42100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare SR One head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with SR One| Date | Company | Stage |
|---|---|---|
| 29 Oct 2026 | Series C+ | |
| 22 Jul 2026 | Series B | |
| 7 Jul 2026 | Series C+ Led | |
| 4 May 2026 | Series B | |
| 24 Mar 2026 | Series A | |
| 22 Jan 2026 | Series C+ | |
| 7 Jan 2026 | Series A Led | |
| 17 Dec 2025 | Series A Led |
Round details for SR One
Amounts, full round histories and every co-investor in SR One's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
42 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Adarx Pharmaceuticals is developing next-generation siRNA therapeutics to treat various diseases. | Healthcare & Biotech | Portfolio page | ||
| Addition Therapeutics is advancing a pipeline of therapeutics to deliver functional cures for patients with severe lifelong diseases | Healthcare & Biotech | Dec 2025Series A | Page + round | |
| AirNexis is developing AN01, a dry powder inhaler for COPD | Healthcare & Biotech | Portfolio page | ||
| Akamis Bio is working to advance the standard of care in colorectal cancer by developing oncolytic immunotherapies | Healthcare & Biotech | Portfolio page | ||
| Alumis Inc is focused on immune-mediated disease therapies | Healthcare & Biotech | Portfolio page | ||
| Ancora Biotech supports the clinical development of multi-specific antibodies for various diseases | Healthcare & Biotech | Portfolio page | ||
| Antag Therapeutics is pioneering a new class of therapies for people living with obesity, diabetes and overweight. | Healthcare & Biotech | Portfolio page | ||
| ARS Pharmaceuticals develops patient-friendly treatments, including a needle-free epinephrine product called neffy | Healthcare & Biotech | Portfolio page | ||
| Asceneuron discovers and develops therapeutics for neurodegenerative disorders | Healthcare & Biotech | Portfolio page | ||
| Avalyn Pharma develops inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. | Healthcare & Biotech | Portfolio page | ||
| Avenzo Therapeutics develops next-generation oncology therapies to transform cancer treatment | Healthcare & Biotech | Sept 2025Series B | Page + round | |
| Bicycle Therapeutics is developing precision-guided therapeutics to target solid tumor cancers and other therapeutic applications | Healthcare & Biotech | Portfolio page | ||
| Biotheryx is advancing a portfolio of first-in-class protein degraders, with an initial focus on validated targets in cancer and inflammatory disease. | Healthcare & Biotech | Portfolio page | ||
| Renalys is involved in creating novel therapies for patients with renal disease | Healthcare & Biotech | Portfolio page | ||
| CHARM Therapeutics is delivering transformational medicines through the understanding of protein-ligand interactions, specifically developing menin inhibitors to treat Acute Myeloid Leukemia (AML). | Healthcare & Biotech | Sept 2025Series B | Page + round | |
| Jan 2026Series C+ | Page + round | |||
| CRISPR Therapeutics is developing gene-based medicines for serious diseases | Healthcare & Biotech | Portfolio page | ||
| Crystalys Therapeutics develops new therapeutics to address unmet medical needs, specifically for people living with gout. | Healthcare & Biotech | Sept 2025Series A · 2 rounds | Page + round | |
| The company is advancing novel, small molecule therapeutic candidates designed to bring functional cures to serious genetic diseases with long-standing unmet need. | Healthcare & Biotech | Portfolio page | ||
| Draig Therapeutics is developing therapies to treat neuropsychiatric disorders | Healthcare & Biotech | Jun 2025Series A | Page + round |
About this data
site last read 5 Nov 2026- Site
- srone.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 17 Nov 2022
- Companies checked
- 42
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get SR One's profile as data
Pull SR One's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/srone.com
# also
GET /v1/firms/srone.com/portfolio
GET /v1/firms/srone.com/coinvestors
GET /v1/firms/srone.com/news